理学博士，副研究员
药物化学，药物设计
电话&传真: +86-，+86-
联系邮箱:zmliu@bjmu.edu.cn
学习经历:
1996-2000 理学学士，北京医科大学药学院药物化学专业
2000-2005 理学博士，北京大学化学与分子工程学院物理化学专业（导师：来鲁华）
任职和工作经历：
2011年-至今 副研究员，北京大学药学院
2005年-2011年 讲师，北京大学药学院
2007年-2009年 “重大新药创制”科技重大专项实施管理办公室
研究方向与兴趣：药物化学与药物设计。
1)发展新的药物设计方法，并将其应用于药物的发现过程。
2)通过设计和结构修饰生物活性分子针对特定的药物靶标寻求找到新的具有应用价值的活性先导化合物。
代表性论文和专著：
1. Liu ZM, Li B, Li X, Zhang L, Lai L. Identification of Small-Molecule Inhibitors against Human Leukocyte Antigen-Death Receptor 4 (HLA-DR4) through a Comprehensive Strategy. J Chem. Inf. Model. 2011, 51: 326-334.
2. Fan D, Liu ZM*, Jin HW, Zhang LR. Classification of Coenzyme a Binding Proteins Based on Co-Factor Binding Modes. Acta Phys Chim Sin. 2011.
3. Tian R, Liu ZM*, Jin HW, Zhang LR, Lin WH. Target Identification of Isomalabaricane Terpenes Extracted from Sponges. Acta Phys Chim Sin. 2011.
4. Zheng Z, Liu ZM*. Application of the HSAB Principle for the Quantitative Analysis of Nucleophilicity/Basicity of Organic Compounds with Lone Pair Electrons. J. Chin Pharmaceu Sci. 2011, 20: 125-132.
5. Bo Li, Zhenming Liu*, Liangren Zhang and Lihe Zhang. Multiple-Docking and Affinity Fingerprint Methods for Protein Classification and Inhibitors Selection. J Chem Inf. Comput. Sci. 2009, 50: 1589-1601.
6. Zheng Z, Liu ZM*, Zhang LR. Combined Method for Determining Reaction Transition State Geometry and Energy. Acta Phys Chim Sin. 2009, 25: 1439-1442.
7. Liu ZM*, Huang CK, Fan KQ, Wei P, Chen H, Liu SY, Pei JF, Shi L, Li B, Yang K, Liu Y, Lai LH. Virtual Screening of Novel Noncovalent Inhibitors for SARS-Cov 3C-Like Proteinase. J Chem Inf. Comput. Sci. 2005, 45: 10-17.
8. Liu ZM*？, Li B and Lai LH. Functional Classification of Phospholipase A2 Family. Acta Phys Chim. Sin. 2005, 21: 1143-1145./
9.Kang LG, Zhang XT, Xie Y, Tu YP, Wang D, Liu ZM, Wang ZY. Involvement of estrogen receptor variant ER-Alpha 36, Not GPR30, in nongenomic estrogen signaling. Mol Endocrinol. 2010, 24: 709-721.
10. Ke YR, Jin HW, Liu ZM, Zhang LR. Homology modeling and structure validation of the Adenosine A(1) receptor. Acta Phys Chim. Sin. 2010,26: 2833-2839.
11.Zhu YQ , Zhu XR, Wu G, Ma YH, Li YJ,Zhao X, Yuan YX, Yang J, Yu S, Shao F, Li RT, Ke YR, Lu AJ, Liu ZM, Zhang LG. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure-activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids. J. Med. Chem. 2010, 53: 1990-1999.
12.Zhang SW, Shi YW, Jin HW, Liu ZM, Zhang LR, Zhang LH. Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study. J. Mol. Model. 2009, 15: 1481-1490.
13. Han D, Meng XB, Wang LN, Liu H, Yao Y, Wang Z, Yang ZJ, Liu ZM, Li ZJ. Efficient synthesis of a series of novel fructose-based 3-acetyl-5-alkyl-2, 3-dihydro-1,3,4-oxadiazole derivatives and studies of the reaction mechanism. Tetrahedron-Asymmetry. 2009, 20: 399-410.
14. Zhang ZL, Wu J, Ran FX, Guo Y, Tian R, Zhou SX, Wang XW, Liu ZM, Zhang LR, Cui JR, Liu JY. Novel 8-deaza-5,6,7,8-tetrahydroaminopterin derivatives as dihydrofolate inhibitor: Design, synthesis and antifolate activity. European J. Med. Chem. 2009, 44: 764-771.
15.Wang YM, Hu LX, Liu ZM, You XF, Zhang SH, Qu JR, Li ZR, Li Y, Kong WJ, He HW, Shao RG, Zhang LR, Peng ZG, Boykin DW, Jiang JD. N-(2,6-Dimethoxypyridine-3-Yl)-9-methyl -carbazole-3-sulfonamide as a novel tubulin ligand against human cancer. Clin Cancer Res. 2008, 14: 6218-6227.
16. Lu X, Chen YL, Guo Y, Liu ZM, Shi YW, Xu Y, Wang XW, Zhang ZL, Liu JY. The design and synthesis of N-1-alkylated-5-aminoaryalkylsubstituted-6-methyluracils as potential non-nucleoside HIV-1 RT inhibitors. Bioorg Med Chem Lett. 2007, 15: 7399-407.
17. Shi YW, Liu ZM, Jin HW, Zhang LR, Zhang LH. Quantitative structure-activity relationships of HIV-1 integrase inhibitors of dkas. Acta Phys Chim. Sin. 2007, 23: 1393-1398.
18. Tian R, Ji YB, Liu ZM, Jin HW, Zhang LR, Lin WH. QSAR and binding mode study of a series of combretastatin analogues as tubulin inhibitors. Chem J. Chinese U. 2007, 28: 2150-2155.
19. Liu Y, Zheng TF, Jin F, Zhou L, Liu ZM, Wei P, Lai LH. Design and bioassay of non-peptidic inhibitors of SARS coronavirus 3C-like Proteinase. Acta Chimica Sinica. 2007, 65: 1707-1712.
20. Lv W, Liu ZM, Jin HW, Yu XH, Zhang LR, Zhang LH. Three-Dimensional structure of HIV-1VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. Org Biomol Chem. 2007, 5: 617-626.
21. Liu P, Guo HZ, Wang WX, Zhang J, Li N, Han J, Zhou JP, Hu YC, Zhang T, Liu ZM, Guo D. Cytotoxic diterpenoids from the bark of Pseudolarix kaempferi and their structure-activity relationships. J. Nat Prod. 2007, 70: 533-537.
22. Pei JF, Wang Q, Liu ZM, Li Q, Yang K, Lai LH. PSI-DOCK: Towards highly efficient and accurate flexible ligand docking. Proteins. 2006 62(4): 934-946.
23. Zhu YQ, Pei JF, Liu ZM, Lai LH, Cui JR, Li RT. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using comfa and comsia methods. Bioorg Med Chem Lett. 2006, 14: 1483-1496.
24. Lai LH, Han XF, Chen H, Wei P, Huang CK, Liu SY, Fan KQ, Zhou L, Liu ZM, Pei JF, Liu Y. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase. Curr Pharm Design. 2006, 12: 4555-4564.
25. Pei JF, Chen H, Liu ZM, Han XF, Wang Q, Shen B, Zhou JJ, Lai LH. Improving the quality of 3D-QSAR by using flexible-ligand receptor models. J Chem Inf. Model. 2005, 45: 1920-1933.
26. Huang CK, Gao Y, Liu ZM, Liu Y, Lai LH. Comparative molecular field analysis of pyrrolidine inhibitors for human cytosolic phospholipase A2. Acta Phys-Chim Sin. 2003, 19: 79-81.